A new thesis from Karolinska Institutet aims to advance our understanding of the bidirectional relationship between ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Organ donation registration can be completed through the Ohio Bureau of Motor Vehicles. Living donors can contact one of two ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...
Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...
Luca was diagnosed with Chronic Kidney Disease. He was added to the waitlist for a deceased donor transplant seven months ago.
Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...